Healthcare Professional Resource - ModernMedicine

Multiple Sclerosis

Editor's Choice
Disease-modifying therapy in adult relapsing-remitting multiple sclerosis
Multiple sclerosis (MS) is a significant cause of disability among young adults, more commonly women, and usually strikes patients in the prime of their lives. Despite recent therapeutic advancements, MS remains an incurable, chronic illness. Clinical evidence supports the role of disease-modifying therapy early in the disease course to reduce the number of acute attacks, delay disease progression, maintain quality of life, and prevent disability.
LATEST ARTICLES
FDA investigating death following first dose of MS drug
FDA announced that it is evaluating the case of a patient with multiple sclerosis (MS) who died 24 hours following administration of the first dose of fingolimod (Gilenya)
New Tool: Rx Adherence Predictor
Now you can determine in advance the likelihood of a patient filling and staying on their medications. This tool can support your ability to prioritize and target patients who may benefit from counseling about the importance of maintaining your prescribed drug regimen.
Drug Watch: Multiple sclerosis agents (PDF) (November 2010)
Agents in late-stage development for the treatment of multiple sclerosis.
Fingolimod: A potential first-in-class oral therapy for the treatment of relapsing-remitting multiple sclerosis
Fingolimod is an investigational drug being studied for the treatment of relapsing-remitting multiple sclerosis (RRMS) and may represent a first-in-class sphingosine 1-phosphate receptor modulator as well as the first oral therapy for the treatment of RRMS.
Disease-modifying therapy in adult relapsing-remitting multiple sclerosis
Multiple sclerosis (MS) is a significant cause of disability among young adults, more commonly women, and usually strikes patients in the prime of their lives. Despite recent therapeutic advancements, MS remains an incurable, chronic illness. Clinical evidence supports the role of disease-modifying therapy early in the disease course to reduce the number of acute attacks, delay disease progression, maintain quality of life, and prevent disability.
eSamples check closet
eSamples check closet
Practice ToolsPractice Tools
Coding Counselor
Coding Counselor

Simple and accurate ICD-9 code search. Start Here

Patient Education
Patient Education

Print customized patient education handouts. Start Here

Dermatology Diagnosis
Dermatology Diagnosis

Identify skin diseases by age, gender, location. Start Here

AHRQ Clinical Guidelines
AHRQ Clinical Guidelines

Objective findings on medical interventions. Start Here



Click here